Raras
Buscar doenças, sintomas, genes...
Febre mediterrânica familiar
ORPHA:342CID-10 · E85.0CID-11 · 4A60.0DOENÇA RARA

A Febre Familiar do Mediterrâneo (FFM) é uma doença autoinflamatória caracterizada por crises curtas e repetidas de febre e inflamação das serosas, que resultam em dores no abdômen, peito, articulações e músculos.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

A Febre Familiar do Mediterrâneo (FFM) é uma doença autoinflamatória caracterizada por crises curtas e repetidas de febre e inflamação das serosas, que resultam em dores no abdômen, peito, articulações e músculos.

Pesquisas ativas
15 ensaios
233 total registrados no ClinicalTrials.gov
Publicações científicas
4.546 artigos
Último publicado: 2026 Apr 3
Medicamentos
3 registrados
COLCHICINE, CANAKINUMAB, ANAKINRA

Tem tratamento?

3 medicamentos registrados
Ver detalhes, fases e interações →
COLCHICINECANAKINUMABANAKINRA

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
>1 / 1000
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
175.0
Turkey
Início
Adolescent
+ adult, childhood, infancy
🏥
SUS: Sem cobertura SUSScore: 0%
1 medicamentos CEAFCID-10: E85.0
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🫃
Digestivo
13 sintomas
🫘
Rins
7 sintomas
🩸
Sangue
3 sintomas
❤️
Coração
3 sintomas
🧠
Neurológico
3 sintomas
🦴
Ossos e articulações
2 sintomas

+ 32 sintomas em outras categorias

Características mais comuns

90%prev.
Febre
Muito frequente (99-80%)
90%prev.
Mialgia
Muito frequente (99-80%)
90%prev.
Artralgia
Muito frequente (99-80%)
90%prev.
Dor abdominal
Muito frequente (99-80%)
90%prev.
Constipação
Muito frequente (99-80%)
90%prev.
Náusea e vômito
Muito frequente (99-80%)
65sintomas
Muito frequente (6)
Frequente (18)
Ocasional (25)
Muito raro (1)
Sem dados (15)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 65 características clínicas mais associadas, ordenadas por frequência.

FebreFever
Muito frequente (99-80%)90%
MialgiaMyalgia
Muito frequente (99-80%)90%
ArtralgiaArthralgia
Muito frequente (99-80%)90%
Dor abdominalAbdominal pain
Muito frequente (99-80%)90%
ConstipaçãoConstipation
Muito frequente (99-80%)90%

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico4.546PubMed
Últimos 10 anos200publicações
Pico2025130 papers
Linha do tempo
2026Hoje · 2026🧪 1994Primeiro ensaio clínico📈 2025Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

1 gene identificado com associação a esta condição. Padrão de herança: Autosomal dominant, Autosomal recessive.

MEFVPyrinDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Involved in the regulation of innate immunity and the inflammatory response in response to IFNG/IFN-gamma (PubMed:10807793, PubMed:11468188, PubMed:16037825, PubMed:16785446, PubMed:17431422, PubMed:17964261, PubMed:18577712, PubMed:19109554, PubMed:19584923, PubMed:26347139, PubMed:27030597, PubMed:28835462). Organizes autophagic machinery by serving as a platform for the assembly of ULK1, Beclin 1/BECN1, ATG16L1, and ATG8 family members and recognizes specific autophagy targets, thus coordinat

LOCALIZAÇÃO

Cytoplasm, cytoskeletonCell projection, ruffleCell projection, lamellipodiumNucleusCytoplasmCytoplasmic vesicle, autophagosome

VIAS BIOLÓGICAS (2)
Purinergic signaling in leishmaniasis infectionThe NLRP3 inflammasome
MECANISMO DE DOENÇA

Familial Mediterranean fever, autosomal recessive

A hereditary periodic fever syndrome characterized by recurrent episodic fever, serosal inflammation and pain in the abdomen, chest or joints. It is frequently complicated by reactive amyloidosis, which leads to renal failure and can be prophylactically treated with colchicine.

EXPRESSÃO TECIDUAL(Tecido-específico)
Sangue
81.4 TPM
Baço
19.9 TPM
Pulmão
10.6 TPM
Testículo
4.1 TPM
Adipose Visceral Omentum
1.9 TPM
OUTRAS DOENÇAS (6)
autosomal recessive familial Mediterranean feversweet syndromefamilial Mediterranean fever, autosomal dominantBehcet disease
HGNC:6998UniProt:O15553

Medicamentos e terapias

COLCHICINEPhase 4

Mecanismo: Tubulin inhibitor

CANAKINUMABPhase 4

Mecanismo: Interleukin-1 beta inhibitor

ANAKINRAPhase 3

Mecanismo: Interleukin-1 receptor antagonist

Ver mais no OpenTargets

Variantes genéticas (ClinVar)

222 variantes patogênicas registradas no ClinVar.

🧬 MEFV: NM_000243.3(MEFV):c.1777G>A (p.Ala593Thr) ()
🧬 MEFV: NM_000243.3(MEFV):c.2176G>A (p.Val726Ile) ()
🧬 MEFV: NM_000243.3(MEFV):c.1006G>T (p.Glu336Ter) ()
🧬 MEFV: NM_000243.3(MEFV):c.1067A>G (p.Gln356Arg) ()
🧬 MEFV: NM_000243.3(MEFV):c.1198C>G (p.Leu400Val) ()
Ver todas no ClinVar

Classificação de variantes (ClinVar)

Distribuição de 1,193 variantes classificadas pelo ClinVar.

418
775
VUS (35.0%)
Benigna (65.0%)
VARIANTES MAIS SIGNIFICATIVAS
LOC126862264: NM_000243.3(MEFV):c.1759+6T>G [Uncertain significance]
MEFV: NM_000243.3(MEFV):c.365A>C (p.Asp122Ala) [Uncertain significance]
MEFV: NM_000243.3(MEFV):c.1147C>T (p.Gln383Ter) [Uncertain significance]
LOC126862264: NM_000243.3(MEFV):c.1727A>G (p.Glu576Gly) [Uncertain significance]
MEFV: NM_000243.3(MEFV):c.1463G>C (p.Gly488Ala) [Uncertain significance]

Vias biológicas (Reactome)

2 vias biológicas associadas aos genes desta condição.

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
Aprovado3
3Fase 31
·Pré-clínico16
Medicamentos catalogadosEnsaios clínicos· 3 medicamentos · 17 ensaios
✓ Aprovados — podem ser usados hoje
COLCHICINECANAKINUMAB
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Febre mediterrânica familiar

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

9 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

233 ensaios clínicos encontrados, 15 ativos.

Distribuição por fase
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

🥈Melhor nível de evidência: Observacional
Timeline de publicações
2.130 papers (10 anos)

Mostrando amostra de 200 publicações de um total de 2.130

#1

Health-related quality of life in children with Familial Mediterranean Fever: a Pediatric Quality of Life Inventory-based evaluation with mutation-specific analysis.

European journal of pediatrics2026 Mar 24

Familial Mediterranean Fever (FMF) is a chronic autoinflammatory disease that may adversely affect health-related quality of life (HRQoL) in childhood. The relative contributions of age, inflammatory burden, and MEFV mutation type to HRQoL impairment remain incompletely clarified. This cross-sectional study included 100 children with FMF and 70 age- and sex-matched healthy controls. HRQoL was assessed using the Pediatric Quality of Life Inventory (PedsQL™) child self-report (ages ≥ 8 years) and parent proxy-report forms. PedsQL scores were compared between groups and across age categories and mutation types. Receiver operating characteristic analysis was performed to determine cut-off values for impaired HRQoL, and multivariate logistic regression was used to identify independent predictors. Total and subscale PedsQL scores were significantly lower in children with FMF compared with controls, particularly in the 8-12 and 13-18 age groups (p < 0.001). Strong correlations were observed between child- and caregiver-reported scores. An overall PedsQL total score < 86 was identified as the optimal cut-off for poor HRQoL. In multivariate analysis, age 8-12 years and elevated C-reactive protein levels (> 3 mg/L) were identified as independent predictors of impaired HRQoL. No significant independent association was observed between MEFV mutation subgroups and HRQoL. HRQoL is significantly reduced in children with FMF, particularly in those aged 8-12 years and in patients with evidence of ongoing inflammatory activity. Inflammatory markers rather than mutation type were associated with impaired HRQoL in this cohort. These findings underscore the importance of routine HRQoL assessment in the clinical follow-up of pediatric FMF patients. • Familial Mediterranean Fever (FMF) is a chronic autoinflammatory disease that can negatively affect health-related quality of life in children. • Previous studies have reported impaired quality of life in FMF; however, the relative impact of age, subclinical inflammation, and mutation status remains unclear. • This study demonstrates that impaired quality of life in pediatric FMF was independently associated with age (8-12 years) and elevated CRP levels rather than MEFV mutation type. • A clinically meaningful Pediatric Quality of Life Inventory (PedsQL) cut-off value is proposed to help identify children at risk for poor quality of life during routine follow-up.

#2

γδ T Cells in Autoinflammatory Diseases.

Cells2026 Feb 24

Autoinflammatory diseases are characterized by inappropriate activation of innate immunity resulting in excessive or persistent inflammation in the absence of infection. γδ T cells possess innate-like properties, including rapid responsiveness to stress-induced self-molecules, phosphoantigens, and inflammasome-derived cytokines, while retaining adaptive effector functions. Neutrophils and macrophages are well-established drivers of autoinflammatory disease, but increasing evidence implicates γδ T cells as key intermediaries by linking innate immune activation to tissue-specific inflammatory pathology. Here, we review evidence that in both monogenic and multifactorial autoinflammatory diseases-including, for example, familial Mediterranean fever, hyper-immunoglobulin (Ig) D syndrome, gout, Behçet's disease, Still's disease, atherosclerosis, and neurodegenerative disorders-γδ T cells display altered frequencies, activation states, cytokine polarization, and tissue recruitment. In inflammasome-driven diseases, skewing of γδ T cells toward interleukin (IL)-17 production has been observed, often accompanied by reduced interferon (IFN)γ secretion, thereby amplifying neutrophilic inflammation and tissue damage. In other diseases, e.g., Behcet's disease, IFNγ and tumor necrosis factor (TNF)α producton predominate. Transcriptomic and tissue-based analyses support the accumulation and functional specialization of γδ T cells at sites of sterile inflammation. Collectively, these findings position γδ T cells as central amplifiers and modulators of inappropriate innate immune activation in the context of autoinflammatory diseases. Improved understanding of γδ T cell subset-specific regulation may inform novel therapeutic strategies targeting autoinflammatory diseases.

#3

Canakinumab treatment in patients with colchicine-resistant familial mediterranean fever: a multicenter observational study.

Turkish journal of medical sciences2026

Anti-interleukin-1 agents have known beneficial effects in the treatment of colchicine-resistant familial Mediterranean fever (cr-FMF); however, studies to date have tended to have small sample sizes and to be based on pooled data. The present study investigates the efficacy of Canakinumab (CAN) in a homogeneous cohort of cr-FMF cases. The study included patients who underwent treatment in three tertiary rheumatology departments, whose electronic medical records were reviewed retrospectively. The inclusion criteria were presence of colchicine resistant disease activity or persistent proteinuria secondary to AA-amyloidosis, and treatment with CAN for at least 6 months. Clinical and laboratory parameters were assessed before and after CAN treatment. The study included 65 patients with a mean age of 38.2 ± 13.8 years, with a mean disease duration of 23.7 ± 11.4 years and a mean colchicine dosage of 1.5 ± 0.6 mg/day. Of the total, 60% of the patients had an M694V homozygous mutation, and 41.5% were resistant to Anakinra. Furthermore, 25 had FMF-related amyloidosis, and 16 were renal transplant recipients. The mean CAN treatment duration was 31.3 ± 23.1 months, and 80% of patients achieved complete remission, while 20% achieved partial remission. Erythrocyte sedimentation rate, C-reactive protein, frequency of attacks, and patient global assessment decreased significantly after CAN (p < 0.001 for each). The mean serum creatinine level (mg/dl) decreased from 2.1 ± 0.8 to 1.4 ± 0.8 (p < 0.001), and median proteinuria (mg/day) decreased from 1475 to 675 (p < 0.001) in patients with AA-amyloidosis. Only one patient with chronic monoarthritis affecting the wrist discontinued CAN due to insufficient arthritis relief. Canakinumab demonstrates excellent efficacy and favorable safety as a treatment for cr-FMF. Our study is the first to indicate the efficacy of CAN in reducing serum creatinine levels.

#4

Comparative analysis of exon 10 and non-exon 10 variants in children with familial mediterranean fever: a retrospective cohort study.

European journal of pediatrics2026 Mar 09

Familial Mediterranean fever (FMF) is the most common inherited autoinflammatory disorder caused by MEFV variants. Exon 10 variants, particularly M694V, are strongly associated with severe disease, but the impact of non-exon 10 variants in children remains less defined. To evaluate genotype-phenotype correlations in pediatric FMF by comparing patients with homozygous exon 10, compound heterozygous exon 10, and exon 10 combined with non-exon 10 variants. This single-center retrospective cohort study included 477 children fulfilling Eurofever/PRINTO criteria between 2018 and 2025. Patients were stratified into four genotype groups. Clinical features, laboratory parameters, and treatments were compared. Disease severity was assessed with the International Severity Scoring System for FMF (ISSF). Homozygous exon 10 variants were associated with an earlier disease onset, shorter diagnostic delay, higher ISSF scores, and a markedly greater requirement for anti-IL-1 therapy compared with other genotypic categories. Patients with compound exon 10 variants and those with combined exon 10-non-exon 10 variants exhibited broadly comparable overall disease severity, although differences were observed in selected clinical manifestations. In contrast, individuals with combined exon 10-non-exon 10 variants demonstrated higher attack frequency, increased inflammatory marker levels, and higher ISSF scores when compared with patients with a single exon 10 allele, supporting a modifier effect of non-exon 10 variants on disease expression. Pediatric FMF patients homozygous for exon 10, especially M694V, show a more severe clinical course with higher disease activity and greater biologic treatment requirements. Exon 10-non-exon 10 variants present with attenuated but clinically relevant phenotypes, resembling compound exon 10 carriers. These findings emphasize the prognostic importance of comprehensive MEFV genotyping in risk stratification and individualized management. • Familial Mediterranean fever (FMF) is the most common monogenic autoinflammatory disorder, caused by MEFV gene mutations. • Exon 10 mutations, particularly M694V homozygosity, are associated with more severe disease, higher attack frequency, colchicine resistance, and increased risk of complications such as amyloidosis. • This is one of the largest pediatric FMF cohorts systematically stratified into homozygous exon 10, compound heterozygous exon 10, exon 10-non-exon 10 groups, and single exon 10 allele • Exon 10-non-exon 10 variant combinations were associated with a clinically relevant inflammatory phenotype resembling compound exon 10 genotypes, suggesting a potential modifier role of non-exon 10 variants.

#5

Clinical, genetic, and therapeutic differences in pediatric versus adult colchicine-resistant FMF patients.

Pediatrics international : official journal of the Japan Pediatric Society2026

Familial Mediterranean Fever (FMF) is a hereditary autoinflammatory disorder characterized by recurrent febrile episodes and serositis. Colchicine-resistant FMF represents a challenging subset of patients with more severe clinical manifestations, limited treatment options, and increased risk of long-term complications. This study aimed to compare clinical manifestations, genetic mutations, comorbidities, and treatment approaches between pediatric and adult patients diagnosed with colchicine-resistant FMF. This retrospective cross-sectional study included 107 colchicine-resistant FMF patients who received biologic treatment at Ankara Bilkent City Hospital between 2018 and 2023. Demographic, clinical, and genetic data were collected and compared between the groups. Treatment response was evaluated using the International Severity Score for FMF (ISSF). A total of 107 patients with colchicine-resistant FMF were included, comprising 38 pediatric and 69 adult individuals. Female predominance was noted in both groups, more prominently in pediatric patients (68.4% vs. 53.6%). Classical FMF symptoms; abdominal pain (100% vs. 89.9%, p = 0.042), fever (97.4% vs. 82.6%, p = 0.025), chest pain (57.9% vs. 24.6%, p = 0.001), and arthritis (50.0% vs. 26.1%, p = 0.013) were significantly more prevalent in pediatric patients. In contrast, adult patients more frequently presented with inflammatory back pain (40.6% vs. 10.5%, p = 0.001), persistent inflammation (24.6% vs. 7.9%, p = 0.039), and amyloidosis (36.2% vs. 2.6%, p = 0.001). Following biological treatment, median ISSF scores decreased significantly in both groups (5.0 to 0.0, p < 0.001). Although overall MEFV mutation distribution was similar between groups (p = 0.574). This study highlights significant age-related differences in clinical presentation and treatment patterns among crFMF patients. Pediatric cases tend to present with a more typical and severe phenotype, while adults exhibit higher rates of complications such as amyloidosis. These findings underscore the need for age-tailored diagnostic and therapeutic approaches in colchicine-resistant FMF.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC3.265 artigos no totalmostrando 195

2026

Health-related quality of life in children with Familial Mediterranean Fever: a Pediatric Quality of Life Inventory-based evaluation with mutation-specific analysis.

European journal of pediatrics
2026

Urological manifestations in familial mediterranean fever excluding renal amyloidosis: a systematic review.

Rheumatology (Oxford, England)
2026

Acute hepatic porphyria masquerading as familial Mediterranean fever: results of a cross-sectional porphobilinogen screening.

Orphanet journal of rare diseases
2026

Sustainability-based assessment using HPLC method for estimation of colchicine and dexamethasone for multi-disease treatment: application to laboratory-made combination and rat plasma.

BMC chemistry
2026

YouTube as a source of information on familial Mediterranean fever.

PeerJ
2026

The Risk of Developing Immune-Mediated Rheumatic Disease Among Adult Patients with Temporomandibular Disorders, a Retrospective Single-Center Cohort Study.

Open access rheumatology : research and reviews
2026

γδ T Cells in Autoinflammatory Diseases.

Cells
2026

Colchicine-Tolerant vs. Resistant Familial Mediterranean Fever: Comparative Analysis of Clinical, Psychosocial Characteristics and Quality of Life.

Journal of clinical medicine
2026

Highlights on the Contribution of Gut Microbiota to Immune-Mediated Diseases in Childhood.

Mediterranean journal of hematology and infectious diseases
2026

The cally index as an indicator of inflammatory burden across clinical phases of familial mediterranean fever.

Clinical rheumatology
2026

Canakinumab treatment in patients with colchicine-resistant familial mediterranean fever: a multicenter observational study.

Turkish journal of medical sciences
2026

Comparative analysis of exon 10 and non-exon 10 variants in children with familial mediterranean fever: a retrospective cohort study.

European journal of pediatrics
2026

Clinical, immunological characterisation and treatment response of patients with syndrome of undifferentiated recurrent fever in Chinese children and adolescents: a single-centre cohort study.

Frontiers in immunology
2026

Large-vessel vasculitis in Behçet's disease carrying MEFV exon 10 variants: A case suggesting a pyrin-associated autoinflammatory background.

Modern rheumatology case reports
2026

Clinical, genetic, and therapeutic differences in pediatric versus adult colchicine-resistant FMF patients.

Pediatrics international : official journal of the Japan Pediatric Society
2026

Correspondence on 'EULAR/PReS endorsed recommendations for the management of familial Mediterranean fever (FMF): 2024 update' by Ozen et al.

Annals of the rheumatic diseases
2026

Evaluation of clinical concordance in FMF siblings with identical biallelic exon 10 variants.

Postgraduate medicine
2026

AI-Powered Detection of Cutaneous Involvement in Familial Mediterranean Fever.

International journal of rheumatic diseases
2026

Colchicine-Treated Familial Mediterranean Fever Patients Are Associated With a Lower Prevalence of Mitral Annular Calcification.

Echocardiography (Mount Kisco, N.Y.)
2026

Real-World Efficacy, Safety, and Drug Retention of Anakinra and Canakinumab in Pediatric Colchicine-Resistant Familial Mediterranean Fever: Insights from a Single-Center Cohort.

Modern rheumatology
2026

Colchicine resistance prediction criteria from the TURPAID cohort do not apply to the JIR cohort: a multicentre descriptive analysis.

RMD open
2026

Familial Mediterranean Fever Presenting with Recurrent Abdominal Pain without Periodic Fever following COVID-19: A Case Report.

Internal medicine (Tokyo, Japan)
2026

Machine-learning algorithms for predicting colchicine resistance in Familial Mediterranean Fever.

Rheumatology (Oxford, England)
2026

The Effect of a Mobile Game Developed for Children with Familial Mediterranean Fever on Disease Management and Quality of Life: A Randomized Controlled Trial.

Games for health journal
2026

Clinical features of patients with familial Mediterranean fever over 50 years of age: a single-center experience.

Internal and emergency medicine
2026

Assessment of colchicine adherence and influencing factors in paediatric familial Mediterranean fever.

Scandinavian journal of rheumatology
2026

Diagnostic Value of the Systemic Immune-Inflammation Index in Differentiating Acute Appendicitis From Familial Mediterranean Fever in Children.

Pediatric emergency care
2026

Evaluation of pediatric FMF patients with biallelic pathogenic exon 10 variants: focus on chest pain.

European journal of pediatrics
2026

Temporomandibular joint ankylosis associated with psoriasis and familial Mediterranean fever: a rare case report.

Journal of stomatology, oral and maxillofacial surgery
2026

Paediatric colchicine poisoning in the UK: a 10-year retrospective case series from the National Poisons Information Service.

Archives of disease in childhood
2026

Genetic, and clinical features in Italian and lebanese subjects with familial mediterranean fever (FMF).

European journal of internal medicine
2026

Inflammatory ankle MRI findings in pediatric and young adult patients with familial Mediterranean fever: a comparison with juvenile idiopathic arthritis and chronic nonbacterial osteomyelitis.

Skeletal radiology
2026

Autonomic dysfunction and its associations with clinical parameters in Familial Mediterranean Fever: a cross-sectional study.

Rheumatology international
2026

Impact of MEFV gene variants on clinical presentation in Familial Mediterranean Fever: A focus on Exon 2 mutations.

Reumatologia clinica
2026

Anti-citrullinated Protein Antibody-positive Arthralgia Associated with an L110P-E148Q Double Heterozygote: A Case-based Review.

Internal medicine (Tokyo, Japan)
2026

Targeting cytokine pathways: the role of biologics in autoinflammatory disorders.

Expert review of clinical immunology
2026

The clinical significance of the Mediterranean fever gene MEFV variants in Castleman disease.

Communications medicine
2026

Cachexia as an unusual presentation of familial Mediterranean fever: A case report.

World journal of clinical cases
2026

The Relationship Between Gene Subtypes, Symptoms, and Cardiac Function in Patients with Familial Mediterranean Fever.

Journal of clinical medicine
2026

Left Ventricular and Left Atrial Strain Characteristics in Patients with Familial Mediterranean Fever Receiving Long-Term Colchicine Therapy.

Diagnostics (Basel, Switzerland)
2026

[Genetic basis of chronic nonbacterial osteomyelitis].

Zeitschrift fur Rheumatologie
2026

Illness perception as a determinant of medication adherence in adult Turkish patients with familial Mediterranean fever.

Clinical and experimental rheumatology
2026

Assessment of Interleukin-33 Levels in Patients with Familial Mediterranean Fever.

Romanian journal of internal medicine = Revue roumaine de medecine interne
2026

Outcomes of assisted reproductive technology in patients with immune-mediated rheumatic diseases: A systematic review and meta-analysis.

Journal of reproductive immunology
2026

How Physicians Manage Colchicine-Resistant Familial Mediterranean Fever: Insights From a Multinational Survey in High-Prevalence Countries.

The Journal of rheumatology
2026

Evaluation of the Effect of IL-1 Antagonists on Pituitary Function.

International journal of endocrinology
2026

Is the decision maker a key determinant of colchicine withdrawal success in paediatric heterozygous familial Mediterranean fever patients?

Scandinavian journal of rheumatology
2025

Familial Mediterranean Fever: A Diagnostic and Therapeutic Challenge.

Cureus
2026

Familial mediterranean fever and long-term cardiovascular disease burden.

The American journal of medicine
2026

Colchicine discontinuation in familial Mediterranean fever: short-term outcomes by pre-discontinuation attack frequency.

Clinical rheumatology
2026

Association of HLA-B alleles with familial mediterranean fever (FMF): A comparative study.

Immunologic research
2026

Efficacy and tolerability of switching from coated to compressed colchicine preparations in patients with Behçet's syndrome.

Rheumatology (Oxford, England)
2026

Colchicine prophylaxis in pediatric PFAPA: a systematic review.

European journal of pediatrics
2026

Familial Mediterranean Fever: A Comprehensive Review of Pathogenesis, Genetics, and Epigenetic Regulation.

Balkan medical journal
2026

Impact of Mediterranean Fever Gene Mutations on Clinical Characteristics in Patients With Inflammatory Bowel Disease.

Gastro hep advances
2025

Co-occurrence of autoimmune diseases and metabolic disorders in familial mediterranean fever patients: review of literature and case reports.

Frontiers in immunology
2025

Growth and pubertal development in children with familial Mediterranean fever under colchicine therapy.

European journal of pediatrics
2026

Nephrotic syndrome genomic discovery in the Mass General Brigham Biobank identifies monoallelic MEFV variants as a risk factor for focal segmental glomerulosclerosis.

Kidney international
2025

Impact of celiac disease on patients with familial Mediterranean fever: a nationwide study based on the Türkiye database.

Frontiers in immunology
2025

Clinical Implications of Vasculitis Associated with Familial Mediterranean Fever: A Comparative Study in Childhood.

Modern rheumatology
2026

Adalimumab-responsive Monogenic Inflammatory Bowel Disease With Pseudopolyposis Characteristic of TGFBR2 Variant in Loeys-Dietz Syndrome.

DEN open
2025

A Case of Familial Mediterranean Fever Diagnosed After Oral Administration of a Gonadotropin-Releasing Hormone (GnRH) Antagonist.

Cureus
2025

Familial Mediterranean Fever With Compound Heterozygosity for the Pyrin Variant L110P-E148Q: A Case Report.

Cureus
2025

Immunogenetics of Behçet's disease: Is there a link to recent phenotypic changes?

Saudi journal of ophthalmology : official journal of the Saudi Ophthalmological Society
2025

Distinct Natural Killer Cell Signature in Still Disease: Insights From a Multinational Immunome Project Consortium for Autoinflammatory Disorders.

Arthritis &amp; rheumatology (Hoboken, N.J.)
2025

Anesthetic Management of a Dental Patient With Familial Mediterranean Fever.

Anesthesia progress
2025

Colchicine in coronary artery and cerebrovascular disease: "Old skin for the new ceremony".

World journal of cardiology
2025

Efficacy and safety of anti-interleukin-6 treatment in familial Mediterranean fever: a systematic literature review.

Reumatologia
2026

SpeckSeq enables high-throughput functional stratification of MEFV variants in autoinflammatory diseases.

The Journal of experimental medicine
2026

Validity of the Eurofever/PRINTO genetic FMF classification criteria in FMF and PFAPA patients carrying non-confirmatory MEFV gene mutations.

Clinical rheumatology
2025

RETRACTED: Kaya et al. The Superiority of Compressed Colchicine Tablets over Coated Colchicine Tablets for Familial Mediterranean Fever. Medicina 2024, 60, 1728.

Medicina (Kaunas, Lithuania)
2025

Assessment of Nutritional Status in Children with Familial Mediterranean Fever Using Prognostic Nutritional Index and Controlling Nutritional Status Score: Relationship with Clinical Findings and MEFV Mutations.

Children (Basel, Switzerland)
2025

Dental Age Estimation by Demirjian, Willems, and Cameriere Methods in Children with Familial Mediterranean Fever: A Case-Control Study.

Children (Basel, Switzerland)
2025

Comparative analysis of conventional and novel inflammatory biomarkers in Familial Mediterranean fever during attack-free periods.

Advances in rheumatology (London, England)
2025

Abdominal Pain Attacks and Angioedema in a Patient With a Homozygous MEFV Mutation: Concurrent FXII Hereditary Angioedema.

Journal of investigational allergology &amp; clinical immunology
2025

Precision genomic profiling in Gaucher disease: insights from atypical presentations.

Frontiers in genetics
2025

Autoinflammatory periodic fever syndromes in preschoolers: neurodevelopmental, behavioral, and maternal psychosocial outcomes.

European journal of pediatrics
2025

Association of Mediterranean diet adherence with familial Mediterranean fever severity in a Lebanese cohort.

Pediatric rheumatology online journal
2025

[What is an undifferentiated systemic autoinflammatory disease in adults? Current state of knowledge in 2025].

La Revue de medecine interne
2026

Increased risk of psoriatic arthritis in patients with familial Mediterranean fever: a population-based cohort study.

Rheumatology (Oxford, England)
2026

Maternal and fetal risks in familial mediterranean fever: focus on adverse pregnancy outcomes.

Clinical rheumatology
2025

Serum resistin levels in pediatric familial Mediterranean fever: Potential biomarker for inflammatory activity.

World journal of clinical pediatrics
2025

[An unusual cause for kidney transplantation].

Innere Medizin (Heidelberg, Germany)
2025

Common features of rare disease patients in the emergency department: a systematised literature review.

Orphanet journal of rare diseases
2025

Correspondence on "comparative evaluation of ChatGPT and LLaMA for reliability, quality, and accuracy in familial Mediterranean fever".

European journal of pediatrics
2025

Familial Mediterranean Fever-Related Peritonitis Visualized on Computed Tomography.

JMA journal
2025

Exploring the Role of MEFV Gene Mutations in Pediatric Drug-Resistant Epilepsy.

Iranian journal of child neurology
2025

Late-onset-case of Familial Mediterranean fever (FMF)-exotic but rising differential diagnosis of "unclear abdominal illness" in Germany due to increasing migration over the past decade.

Wiener medizinische Wochenschrift (1946)
2026

Phenotypes of patients with more than one autoinflammatory disease-associated gene variant: overlapping and mixed autoinflammatory disorders.

Rheumatology (Oxford, England)
2025

Idiopathic Recurrent Serositis: A Multispecialty Challenge Resolved With Colchicine.

Cureus
2025

The clinical management of adult patients with Familial Mediterranean fever.

Expert review of clinical immunology
2026

ChatGPT, Gemini, and Grok on familial mediterranean fever: are they trustworthy?

Clinical rheumatology
2025

From ulcerative colitis to amyloid storm: a case-based review.

Rheumatology international
2025

Pediatric COPA Syndrome Overlapping With Heterozygous Familial Mediterranean Fever: A Dual Inflammatory Disorder.

Case reports in pediatrics
2025

Successful multimodal intensive care management including early plasmapheresis and granulocyte colony stimulating factor in severe colchicine poisoning: A case report.

Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
2025

A semi-automated ASC speck assay to evaluate pyrin inflammasome activation.

Clinical &amp; translational immunology
2025

Effect of MEFV mutations and HLA-B27 on clinical findings of familial Mediterranean fever and spondyloarthritis.

Medicine
2025

A single dose of anakinra for arresting familial Mediterranean fever attacks: a proof-of-concept study.

Clinical and experimental rheumatology
2025

What Large Language Models offer about Familial Mediterranean Fever: An Analysis of Quality, Readability, Completeness, and Accuracy.

Mediterranean journal of rheumatology
2025

Scrotal Pain in Familial Mediterranean Fever: A Series of Three Case Reports and Literature Review.

Mediterranean journal of rheumatology
2025

Retinal clues to subclinical inflammation in familial Mediterranean fever.

Pediatric research
2025

Liver function changes in pediatric FMF: exploring disease dynamics and therapy impacts.

European journal of pediatrics
2025

Overlap of familial Mediterranean fever and APLAID treated with anakinra: a case-based review.

Clinical rheumatology
2025

First Genetically Confirmed Case of Familial Mediterranean Fever in Somalia: A Case Report and Diagnostic Challenges in Resource-Limited Setting.

International medical case reports journal
2025

Effect of colchicine in heart failure patients with metabolic syndrome: Focus on inflammatory mechanisms.

Biomedicine &amp; pharmacotherapy = Biomedecine &amp; pharmacotherapie
2025

Impact of Colchicine Therapy on Ventriculoarterial Coupling in Familial Mediterranean Fever: A Cross-Sectional Study.

Journal of clinical medicine
2025

Evaluation of biological treatment in pediatric patients with familial Mediterranean fever: a retrospective study of 832 patients.

Expert opinion on biological therapy
2025

Grisel syndrome in pediatric rheumatic diseases as a rarely recognized complication: case-based review.

Clinical rheumatology
2025

The effect of health literacy on colchicine adherence in adolescents with familial Mediterranean fever.

Postgraduate medicine
2025

The decline of AA amyloidosis in familial Mediterranean fever is significant, but the story is not over.

Clinical and experimental rheumatology
2026

Real-world Use of Canakinumab in Familial Mediterranean Fever and Other Autoinflammatory Disorders: A Medical Records Review Single-center Study From Turkey.

Journal of clinical rheumatology : practical reports on rheumatic &amp; musculoskeletal diseases
2025

Prevalence, incidence and geographic distribution of familial Mediterranean fever in Turkey: a national cohort study.

Clinical and experimental rheumatology
2025

Preliminary Evidence for Sex-Specific Trends in Probiotic Modulation of Gut Saccharibacteria in Familial Mediterranean Fever Patients: Effects of Lactobacillus acidophilus INMIA 9602 Er 317/402 and Escherichia coli M-17.

International journal of molecular sciences
2025

Serum Galectin-3 and Presepsin Levels in Pediatric Familial Mediterranean Fever Patients During Remission: A Prospective Study.

Diagnostics (Basel, Switzerland)
2025

Comparative analysis of global practices in the management of colchicine-resistant familial Mediterranean fever: a CliPS network analysis.

RMD open
2025

Immature granulocyte percentage: a practical marker of acute ınflammation in pediatric familial mediterranean fever: A retrospective observational case-control study.

Clinical rheumatology
2025

PSTPIP1 and pyrin, two key regulators of macrophage differentiation.

European journal of cell biology
2025

Identification of pathogenic MEFV variants in Korean patients with familial Mediterranean fever via whole-genome sequencing: a case report.

Journal of rheumatic diseases
2025

Development and Validation of a Rapid and Simple UHPLC-MS/MS Method for the Determination of Colchicine in Human Plasma.

Biomedical chromatography : BMC
2025

S100A9 promotes inflammasome-dependent autoinflammation by blocking the degradation of SYK tyrosine kinase.

Journal of leukocyte biology
2025

Familial Mediterranean fever and reproductive systems, our experience in two decades: A letter to editor.

International journal of reproductive biomedicine
2025

The impact of homozygous mutations in exon 10 on musculoskeletal findings in children with familial mediterranean fever.

European journal of pediatrics
2025

Physical Activity Levels of Adolescents with Familial Mediterranean Fever.

Clinical pediatrics
2025

Evaluation of rheumatic causes underlying childhood-onset arthritis.

Turkish journal of medical sciences
2025

Mevalonate kinase deficiency in a familial Mediterranean fever endemic region: a single-center experience.

The Turkish journal of pediatrics
2025

Obstetric and neonatal outcomes in pregnancies with familial mediterranean fever: a comparative study.

Rheumatology international
2025

Familial Mediterranean fever (FMF) complicated by adhesive small bowel obstruction: a diagnostic challenge.

BMJ case reports
2025

Non-canonical manifestations of FMF in homozygous M694V MEFV genotype: Insights from a large patient cohort.

Seminars in arthritis and rheumatism
2025

Neurological involvement in children with familial Mediterranean fever: a systematic review.

Pediatric rheumatology online journal
2025

Immune-Related Comorbidities in Pediatric Familial Mediterranean Fever: A Hidden Burden beyond Autoinflammation.

International archives of allergy and immunology
2025

Adhesive small bowel obstruction with familial Mediterranean fever, case series and literature review.

International journal of surgery case reports
2025

Transcriptome analysis of unmedicated heterozygous familial Mediterranean fever patients reveals a type I interferon signature driving increasing Pyrin expression.

Annals of the rheumatic diseases
2025

Vasculitis as an indicator of disease severity in familial Mediterranean fever.

Frontiers in immunology
2025

Diagnostic Utility of the Ocular Surface Test for Psoriasis-Associated Conjunctivitis: A Case Report.

Cureus
2025

The impact of peer victimization and psychological symptoms on quality of life in children and adolescents with FMF.

Pediatrics international : official journal of the Japan Pediatric Society
2026

Vasculitis in autoinflammatory diseases.

Current opinion in rheumatology
2025

The effects of self-efficacy in managing the disease and disease adaptation levels of Familial Mediterranean Fever (fmf) patients on satisfaction with life: a web-based cross-sectional study.

Orphanet journal of rare diseases
2025

Nutritional status in children with familial Mediterranean fever.

Postgraduate medicine
2025

[Use of IL-1 inhibitors in the treatment of familial Mediterranean fever in pediatric rheumatology].

Zeitschrift fur Rheumatologie
2025

Differentiating familial Mediterranean fever attacks from acute appendicitis in children: which laboratory parameters are useful?

Scandinavian journal of rheumatology
2025

Predictive factors for therapeutic response and cluster analysis in syndrome of undifferentiated recurrent fever (SURF).

RMD open
2025

The Turkish Pain Catastrophizing Scale-Child in Adolescents with Familial Mediterranean Fever: A Psychometric Analysis.

Archives of rheumatology
2025

A Unique Complex Variation Profile in a Patient with Familial Mediterranean Fever (FMF): Triple Homozygous E148Q-P369S-R408Q - "Case Report".

The application of clinical genetics
2025

Three-year follow-up of canakinumab dose extension in children with colchicine-resistant familial Mediterranean fever: PeRA-RG Experience.

Rheumatology (Oxford, England)
2025

Vascular characteristics of pediatric patients with familial Mediterranean fever: a study of optical coherence tomography angiography findings.

Japanese journal of ophthalmology
2025

Familial Mediterranean Fever as a Cause of Recurrent Pleurisy in a Child With Crohn's Disease: A Case Report.

Case reports in pulmonology
2025

[Clinical characteristics and treatment outcomes in patients with recurrent pericarditis].

Zhonghua xin xue guan bing za zhi
2026

"What do patients do during a familial Mediterranean fever attack? Their strategies and associated factors: a critical appraisal.

Internal and emergency medicine
2026

Reported Triggers and Self-reported Management Strategies in Children With Familial Mediterranean Fever.

Journal of clinical rheumatology : practical reports on rheumatic &amp; musculoskeletal diseases
2025

Case Report: Sacroiliitis in Familial Mediterranean Fever Mimicking Septic Arthritis-A Diagnostic Challenge.

International journal of rheumatic diseases
2025

Mediterranean fever gene variants may prevent the development of lupus nephritis in Japanese patients with systemic lupus erythematosus.

Frontiers in immunology
2025

Comparative evaluation of ChatGPT and LLaMA for reliability, quality, and accuracy in familial Mediterranean fever.

European journal of pediatrics
2025

Change in Gasdermin-D gene expression in familial Mediterranean fever compared to healthy children with or without acute infections.

The Turkish journal of pediatrics
2025

Impact of Familial Mediterranean Fever on Choroidal Tissue: A Study of Choroidal Thickness and Vascularity in Pediatric Patients.

Ocular immunology and inflammation
2025

Utilization of disease activity scores and acute phase reactants in predicting colchicine response assessed by FMF50: a retrospective cohort study in children with Familial Mediterranean Fever.

Clinical rheumatology
2025

Concomitant Systemic Autoinflammatory Diseases: Diagnostic and therapeutic challenges.

Sultan Qaboos University medical journal
2025

A Case of Colchicine Overdose and Toxicity.

Cureus
2025

Prevalence of neurological manifestation in familial mediterranean fever patients: systematic review & meta-analysis.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
2025

Navigating Bariatric Surgery in Familial Mediterranean Fever.

Obesity surgery
2025

Guided management of familial Mediterranean fever.

Nature reviews. Rheumatology
2025

Sclerosing encapsulating peritonitis as a rare complication of familial Mediterranean fever.

Rheumatology (Oxford, England)
2025

Pediatric Immunoglobulin A Vasculitis: Impact of Mediterranean Fever Gene Variants on Clinical Course and Inflammatory Markers.

Turkish archives of pediatrics
2025

Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Cervical Adenitis (PFAPA) Syndrome in Children-From Pathogenesis to Treatment Strategies: A Comprehensive Review.

Paediatric drugs
2025

Periodontitis and Mediterranean fever: a systematic review and metaanalysis.

Quintessence international (Berlin, Germany : 1985)
2025

The role of epigenetic modifications in systemic autoinflammatory diseases.

Current opinion in immunology
2025

Clinical features and novel pathogenic variants of patients with Behçet's disease like trisomy 8.

Orphanet journal of rare diseases
2025

M694I variant of MEFV drives pathogenesis of familial Mediterranean fever through enhanced Th17 cell differentiation.

Rheumatology (Oxford, England)
2025

What do patients do during a familial Mediterranean fever attack? Their strategies and associated factors.

Internal and emergency medicine
2025

Transient elastography measurements of the liver and transplanted kidney in patients with AA amyloidosis: a cross-sectional comparative study.

Rheumatology international
2025

[Genetic diagnostics in fever syndromes].

Zeitschrift fur Rheumatologie
2025

AA amyloidosis with multiorgan involvement secondary to familial Mediterranean fever (FMF): dreadful consequences of delayed diagnosis and management.

BMJ case reports
2026

Accurate Diagnosis of Familial Mediterranean Fever Improved Quality of Life for a Patient and Her Family: A Case Report.

Journal of Nippon Medical School = Nippon Ika Daigaku zasshi
2025

Efficacy and safety of treatments in familial Mediterranean fever and its complications: a systematic review informing the EULAR/PReS recommendations for familial Mediterranean fever.

Annals of the rheumatic diseases
2025

Genetic Basis of Autoinflammatory Skin Diseases. Part I. Genetic Pathways of Complex Autoinflammatory Skin Diseases.

Journal of the American Academy of Dermatology
2025

Re-evaluation of MEFV carriers previously diagnosed with FMF: a colchicine discontinuation study.

Rheumatology (Oxford, England)
2025

Unresolved Issues in Familial Mediterranean Fever: Is p.R202Q MEFV Variant Potentially Pathogenetic in Unleashing Inflammation?

Journal of clinical immunology
2025

The Mediterranean spring-the second revolution (and the first) in the management of familial Mediterranean fever.

Annals of the rheumatic diseases
2025

Retinal changes in children with Familial Mediterranean Fever: the effect of chronic subclinical inflammation.

Pediatric research
2025

Prophylactic colchicine for familial Mediterranean fever: response rates revisited.

Scandinavian journal of rheumatology
2025

Canakinumab treatment patterns in sJIA, FMF, TRAPS, and MKD/HIDS: real-world insights from a Belgian non-interventional study.

BMC rheumatology
2025

Evaluation of anti-HBs seropositivity rates in children with familial mediterranean fever.

European journal of pediatrics
2025

What do patients with familial Mediterranean fever and the doctors who prescribe it know about colchicine? Results of a national survey of 255 patients and 203 doctors in France.

La Revue de medecine interne
2026

Investigation of the expression levels of MEFV gene in patients with frequent MEFV pathogenic variants in Kahramanmaras (Turkey).

Nucleosides, nucleotides &amp; nucleic acids
2025

Successful treatment with tocilizumab in a case of familial Mediterranean fever with Takayasu arteritis.

Modern rheumatology case reports
2025

Efficacy and Safety of Anakinra in Colchicine-Resistant or -Intolerant Familial Mediterranean Fever: A Single-Center Real-Life Experience.

Medicina (Kaunas, Lithuania)
2025

Genetic Variants in Early-Onset Inflammatory Bowel Disease: Monogenic Causes and Clinical Implications.

Children (Basel, Switzerland)
2025

Global research trends and hotspots in erysipelas: a bibliometric analysis from 2000 to 2024.

Frontiers in medicine
2025

Pulmonary Findings in Children With Colchicine-Resistant Familial Mediterranean Fever.

Pediatric pulmonology
2025

Selective immunoglobulin E deficiency and its association with autoimmune and autoinflammatory diseases.

Allergy and asthma proceedings
2025

Genotype-phenotype correlations and resistance to colchicine in a familial Mediterranean fever cohort in southwestern Spain.

European journal of internal medicine
2025

Evaluation of Plasma Soluble Cd40 Ligand Levels in Children with Familial Mediterranean Fever and Its Relationship with Carotid Intima-Media Thickness.

Diagnostics (Basel, Switzerland)
2025

Hyperimmunoglobulinemia D Syndrome Masquerading as Familial Mediterranean Fever, Hidradenitis Suppurativa, and Crohn's Disease: A Case Report.

Saudi journal of medicine &amp; medical sciences
2025

Genetic and clinical features of familial Mediterranean fever in a cohort of patients with kidney failure.

Journal of nephrology
2025

Elevated serum levels of interleukin-18 discriminate Still's disease from other autoinflammatory conditions: results from the European ImmunAID cohort.

RMD open
2025

Vaccine hesitancy among parents of children with chronic diseases of different pathophysiology: a cross-sectional study in Sivas, Türkiye.

BMC public health
Ver todos os 3.265 no EuropePMC

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Febre mediterrânica familiar.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Febre mediterrânica familiar

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Health-related quality of life in children with Familial Mediterranean Fever: a Pediatric Quality of Life Inventory-based evaluation with mutation-specific analysis.
    European journal of pediatrics· 2026· PMID 41874655mais citado
  2. &#x3b3;&#x3b4; T Cells in Autoinflammatory Diseases.
    Cells· 2026· PMID 41827822mais citado
  3. Canakinumab treatment in patients with colchicine-resistant familial mediterranean fever: a multicenter observational study.
    Turkish journal of medical sciences· 2026· PMID 41816744mais citado
  4. Comparative analysis of exon 10 and non-exon 10 variants in children with familial mediterranean fever: a retrospective cohort study.
    European journal of pediatrics· 2026· PMID 41801261mais citado
  5. Clinical, genetic, and therapeutic differences in pediatric versus adult colchicine-resistant FMF patients.
    Pediatrics international : official journal of the Japan Pediatric Society· 2026· PMID 41782418mais citado
  6. Modulation of Inflammasome Activity by miR-197-3p in Familial Mediterranean Fever Mouse Macrophages.
    Arch Rheumatol· 2026· PMID 41989452recente
  7. Effect of inspiratory muscle training on fatigue, aerobic capacity, pulmonary functions, and quality of life in adolescents with familial Mediterranean fever: a randomized controlled trial.
    Ir J Med Sci· 2026· PMID 41979792recente
  8. Severe tortuosity but not altered retinal vessel diameters in children and young adults with Familial Mediterranean Fever: a case-control study.
    Rheumatol Int· 2026· PMID 41968195recente
  9. Age-related decline in FMF activity: biological signal or modeling artifact?
    Intern Emerg Med· 2026· PMID 41961245recente
  10. Case Report: Gitelman syndrome with a suspected MEFV- associated autoinflammatory phenotype: diagnostic challenges in a complex case.
    Front Immunol· 2026· PMID 41958666recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:342(Orphanet)
  2. MONDO:0018088(MONDO)
  3. GARD:6421(GARD (NIH))
  4. Variantes catalogadas(ClinVar)
  5. Busca completa no PubMed(PubMed)
  6. Artigo Wikipedia(Wikipedia)
  7. Q1144618(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Febre mediterrânica familiar
Compêndio · Raras BR

Febre mediterrânica familiar

ORPHA:342 · MONDO:0018088
🇧🇷 Brasil SUS
CEAF
1ACanaquinumabe
Geral
Prevalência
>1 / 1000
Herança
Autosomal dominant, Autosomal recessive
CID-10
E85.0 · Amiloidose heredofamiliar não-neuropática
CID-11
Ensaios
15 ativos
Medicamentos
3 registrados
Início
Adolescent, Adult, Childhood, Infancy
Prevalência
175.0 (Turkey)
MedGen
UMLS
C0031069
Repurposing
22 candidatos
aspirincyclooxygenase inhibitor
chloramphenicolbacterial 50S ribosomal subunit inhibitor
chloramphenicol-palmitateprotein synthesis inhibitor
+17 outros
EuropePMC
Wikidata
Wikipedia
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades